Allopurinol for the treatment of essential hypertension (EHTN) Farahnak Assadi, MD Emeritus...

Allopurinol for the treatment of essential hypertension (EHTN)

Farahnak Assadi, MDEmeritus Professor of PediatricsChief Section of Nephrology

Why Do Some People Develop EHTN?

Normal Weight/BP (60-80%)Obese/HTN (20-40%)

??

Obese/HTN: Overeat and exercise less BUT WHY?

Why Do Some Kids Develop EHTN?

Normal Weight/BP(80-90%)Obese/HTN (10-20%)

??

Obese/HTN: Overeat and exercise less BUT WHY?

Developmental Basis of Obesity HTN

Data indicating that obesity HTN has its origins during development and environmental chemicals exposures play a major role

A bad startthat lastsa lifetime!

When Do Diseases Actually Start, and What Causes Diseases?

Epigenetic(stable but plastic)

Genetic polymorphisms

(born with)

Inter-individual variability

Environmental factors

Susceptibility to Disease, Toxicants, Drugs, Altered behavior

(chemicals, diet, drugs, stress, behavior)

Both Genetics and Environment Factors Control Our Life

Epigenetic Causes of Overeating and Lack of Exercise?

• Drug use (steroids, antidepressants, other meds?)

• Exposure to viruses (adenovirus 36)

• Environment– Stress (increased glucocorticoids)

– Nutrition (dietary salt)

– Lack of sleep

– Environmental chemicals

Epidemiologic studies

• In Japanese the incidence of ETN approaches 50%• The mean sodium intake in Japanese is >400

mmol/day.• In Eskimo the average sodium intake is very low

<50 mmol/day and EHTN is virtually nonexistent.

©2007 RUSH University Medical Center

Renal Handling of Sodium

• Excessive sodium intake alone is not sufficient to cause HTN, because the sodium retention and ECF volume expansion result in increased urinary sodium excretion that eventually normalize cardiac output and BP.

• Additional predisposing factors must exist that lead to the development of HTN in certain individual when the sodium intake is >60-70 mmol/day.

• Guyton AC. Hypertension 1987;10:1-6

©2007 RUSH University Medical Center

©2007 RUSH University Medical Center

The role of kidney in SHR

Rettig R. J Human Hypertens 1993:7:177-180

Role of kidney in Human EHTN

• In patients with ESRD due to EHTN, bilateral nephrectomy and a well-functioning allograft from a normotensive cadaver, cures EHTN

• Incidence of EHTN in recipients of cadaver kidneys correlates with the incidence of EHTN in the family of donors

• Curttis jj et al. N Engl J Med 1983;309:1009=1015• Guidi E, et al. Nephron 1985;41:14-21

©2007 RUSH University Medical Center

Genes Causing EHTN

• Aldosterone synthesis gene (CYp11B2) mutations.

• Angiotensin II type 1 receptor gene (ATI) polymorphism.

• Endothelial nitric oxide synthesis gene (eNOS) mutations.

• G-protein β3 subunit gene (GNβ3) variant. • Caulfield M et al N Engl J Med 1994;330:1629-1633

• Benjafield AV et al. Hypertens.1998;32:1094-1097

• Siffert W, et al. Nat Genetics 1998;18:45-48

• Davies E, et al. Hypertens. 1999;33:703-707

Impaired natriuresis: a prerequisite in EHTN• Increase ECF volume• Na/K ATPase inhibition• Increase ICF sodium concentration• Increase ICF calcium concentration• Vasoconstriction• Increase systemic vascular resistance• Development of EHTN

©2007 RUSH University Medical Center

Blaustein MP. Hypertension 1984;6:445-453

Pathogenesis of EHTN

• There is a genetically predetermined impairment in the renal ability to excrete sodium or “impaired natriuretic capacity.”

• The prevalence of EHTN among offspring has been reported to be 46% if both parents are hypertensive, and 28% if one parent is hypertensive, and only 3% if neither parent is hypertensive.

©2007 RUSH University Medical Center

Ayman D. Arch Intern Med 1934;53:792-802

Essential hypertension(EHTN)

• EHTN is a public Health problem worldwide and its burden on our health care system is becoming enormous.

• Many children with obesity are not aware that they have HTN.

• Over activity of renin-angiotensin system (RAS) is the main cause of primary HTN.

• RAS over activity can lead to myocardial hypertrophy, CVD and CKD and stoke.

©2007 RUSH University Medical Center

Douglas JG et al. Arch Intern Med 2003;163:525-541

Reversal of LV Hypertrophy By Antihypertensive Treatment

Schmieder RE et al. JAMA. 2006

Ch

ang

e in

LV

mas

s in

dex

(%)

0

-5

-10

-15

-20

-25

Diuretics blockers

Calciumchannelblockers

ACE inhibitors

p<.01

p<.01

7%6%

9%

13%

Uric acid and EHTN

• EHTN is frequently associated with hyperuricemia in both adult and pediatric patients.

• More than 60% of children with EHTN have serum uric acid (UA) levels above 5.5 mg/dL.

• UA causes HTN through the activation of the RAS, down regulation of nitric oxide, and vascular endothelial dysfunction.

• Elevated UA level is a predictor of incident HTN and cardiovascular disease.

• Feig DI et al. JAMA 2008;300:924-932

Hypothesis

• Treating EHTN with usual antihypertensive agents does not completely reduce cardiovascular risk related to uric acid (UA) levels.

• Lowering serum UA levels with allopurinol may provide greater benefit than simply treating HTN with the conventional therapy.

Purpose of the study

• ACE inhibition in combination with allopurinol may reduce BP more effectively than ACE inhibitor alone in hyperuricemic children with newly diagnosed EHTN.

Patients

• Forty- four children, aged 7-19 years, with newly diagnosed, never treated EHTN and serum UA levels > 5.5 mg/dL were studied.

• Patients were randomized in to two groups. Group 1 (n=20) received enalepril (0.3 mg/kg twice daily) for 8 weeks.

• Group 2 (n=24) received enalepril in combination with allopurinol (100 mg twice daily) for 8 weeks.

Exclusion criteria

• Patients excluded if they had pre-HTN, stage 2 HTN, white-coat HTN or known renal, endocrine, gastrointestinal tract, hepatic or CVD.

• Also excluded were patients with a fasting blood sugar greater than 110 mg/dL,hemoglobin A1C greater that 6%, CVD, had treated with medications known to cause high BP or increase serum UA level.

Characteristic Enalepril therapy (n=20)

Combined therapy

(n=24)

P value

Gender (N) Male (23)

Female (19)

Male (27)

Female (15)

NS

NS

Age, mean (year) 14.2 15.9 NS

BMI (%) 87 (86-89) 86 (85-90) NS

Systolic BP

(mmHg)

133 (129-136) 134 (128-137) NS

Diastolic BP (mmHg)

85 (82-86) 86 (80-97) NS

Serum UA

(mg/dL)

6.6 (5.9-7.4) 6.8 (6.1-7.6) NS

FEUA (%) 10.8 (8.1-12.3) 12.1 (8.7-12.4) NS

Patient population (pretreatment)

Methods

• Random urine samples were collected for routine urinalysis and determinations of sodium and uric acid levels.

• Blood samples were drawn for electrolytes, creatinine and uric acid concentrations.

• Fractional excretion of uric acid were calculated using the standard formula.

Parameter Mono therapy (GI)

(n=20)

Combined therapy (G II) (n=24)

P value

Change in systolic BP (mmHg)

-4.3 (-2.1 to -6.7) -8.2 (-7.2 to -9.8) 0.001

Change in diastolic BP

-2.4 (-1.1 to -2.2) -6.3 (-1.9 to -7.8) 0.006

Serum uric acid (mg/dL)

-5.1 (-5.8 to-6.7) -3.3 (-2.9 to-5.2) 0.002

FEUA

(%)

-3.3 (-3.4 to-4.1) -5.4 (-4.4 to-8.0) 0.004

Results

Conclusions

• Allopurinol in combination with enalepril can reduce BP more effectively than enalepril alone in hyperuricemic children with newly diagnosed EHTN.

• Strategies to lower the risk of CVD in children with EHTN should include monitoring serum uric acid level treatment regimens that lower uric acid may be indicated to decrease the incidence of CVD by reducing serum uric acid level.

Future Direction

• Increased dietary intake of fructose, which is a known cause of hyperuricemia, may be contributing to the current epidemic of obesity and HTN.

• Ongoing clinical trials will elucidate the role of uric acid in human HTN and will determine whether control of uuric acid may be a new way to prevent or treat EHTN.

The End….but just the beginning

©2007 RUSH University Medical Center

Peripheral vascular disease

Morbidity

Disability

CKD

CADCHFLVHStroke

Hypertension

National High Blood Pressure Education Program Working Group, 2012

Hypertension (HTN): A Significant CV and Renal Disease Risk Factor

Prevalence of CVD

10 20 30 40 50 60

High BP

CAD

CHF

Stroke

Other

50,000,000

12,200,000

4,600,000

4,400,000

2,800,000

Prevalence (millions)

BP=blood pressure, CAD=coronary artery disease, CHF=congestive heart failure

• Estimated Number of Persons With CVD in the US

(24%)

American Heart Association® . 2000 Heart and Stroke Statistical Update. 2009

The Metabolic Syndrome*

*Diagnosis is established when 3 of these risk factors are present.†Abdominal obesity is more highly correlated with metabolic risk factors than is BMI. ‡Some men develop metabolic risk factors when circumference is only marginally increased.

Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. JAMA. 2001;285:2486-2497.

<40 mg/dL<50 mg/dL

MenWomen

>102 cm (>40 in)>88 cm (>35 in)

MenWomen

110 mg/dLFasting glucose130/85 mm HgBlood pressure

HDL-C150 mg/dLTG

Abdominal obesity† (Waist circumference‡)

Defining LevelRisk Factor

Dietary Approaches to Stop Hypertension (DASH)

• Diet high in fruits and vegetables and low-fat dairy products lowers blood pressure (11 mmHg SBP/ 5 mmHg DBP lower than traditional US diet), including more than a sodium-restricted diet

• Recommends 7-8 servings/day of grain/grain products, 4-5 vegetable, 4-5 fruit, 2-3 low- or non-fat dairy products, 2 or less meat, poultry, and fish

NEJM 1997; 366: 1117-24

Lifestyle Modification

Modification Approximate SBP reduction(range)

Weight reduction 5–20 mmHg/10 kg weight loss

Adopt DASH eating plan

8–14 mmHg

Dietary sodium reduction 2–8 mmHg

Physical activity 4–9 mmHg

Moderation of alcohol consumption

2–4 mmHg

Indications for Antihypertensive Drug Therapy in Children

with Stage 1 HTN

• Persistent HTN despite non-pharmacologic measures

• Symptomatic HTN• Secondary HTN• Hypertensive target-organ damage• Diabetes (types 1 and 2), CKD, obesity

Evaluation: The Four Questions

• What is the cause of my hypertension?

– Primary hypertension most prevalent but secondary causes more common than in adults

– The younger the child and the more severe the hypertension; the more likely to be a secondary etiology

• What do we do about all this?

Algorithm for Treatment of EHTN

Not at Goal Blood Pressure >95 percentile (in adolescents>125/75 mmHg even if less the 90 percentile)

Initial Drug Choices

Drug(s) for the compelling indications

Other antihypertensive drugs (diuretics, ACEI, ARB, BB, CCB)

as needed.

With Compelling Indications

Lifestyle Modifications

Stage 2 Hypertension (>95th percentile + 5 mmHg) 2-drug combination for most

(usually thiazide-type diuretic and ACEI, or ARB, or BB, or CCB)

Stage 1 Hypertension

Between 95th and 99th percentile plus 5 Thiazide-type diuretics for most.

May consider ACEI, ARB, BB, CCB, or combination.

Without Compelling Indications

Not at Goal Blood Pressure

Optimize dosages or add additional drugs until goal blood pressure is achieved.

Consider consultation with hypertension specialist.

Evaluation: The Four Questions

• Am I really hypertensive?Repetitive measurements/ABPM

• What risk factors for CVD do I have?Prmaturity, low birth weight, family history of

diabetes, hypercholesterolemia, CKD • What has HTN done to my body?

Look for end organ damage• CVD, CKD or stroke; • Evaluation of subtle subclinical changes

(microalbuminuria, non-dipper)

Defining Pediatric HTN in children

Normal blood pressure BP <90th percentile

Pre-hypertension BP between 90th and 95th percentile, or if BP >125/75 mmHg even if < 90th percentile

Stage 1 hypertension BP between 95th and 99th percentile plus 5 mmHg

Stage 2 hypertension BP > 99th percentile + 5 mmHg

*Average SBP and DBP, on >3 occasions **Average SBP or DBP, on >3 occasions

The 4th Task Force Report on High BP in Children and Adolescents Pediatrics 2004; 114:555-574

Causes of pediatric HTN

• Primary HTN is most prevalent• Secondary causes is more common than in

adults• The younger the child and the more severe

the HTN; the more likely to be a secondary etiology

©2007 RUSH University Medical Center

Practical approach to diagnosis of HTN

Obtain UA, BMP, lipid profile, renal sonogram, ECHO

Normal Abnormal UA Abnormal sonogram Metabolic alkalosis

C3, ANA, ANCA Diuretic scan, VCUG DTPA scan, PRA/Aldo, MRA

Essential GN UPJ,VUR RVH, Hyperaldostronim

©2007 RUSH University Medical Center

Kidneys

Increased intraglomerular pressure

Increased protein leak

Glomerular growth and fibrosis

Increased sodium reabsorption

Decreased renal blood flow

Adapted from Opie and Gersh. Drugs for the Heart, 2001

Potential Pathogenic Propertiesof Angiotensin II